TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05586074

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clifutinib
Description: tablet, oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LoDAC
Description: subcutaneous (SC) or intravenous (IV) injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azacitidine
Description: SC or IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine
Description: IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ara-C±IDA
Description: SC and IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FLAG-IDA
Description: SC and IV
Study: NCT02503189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KCT-0809 ophthalmic solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04625946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor
Description: Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.

Intervention type: DEVICE
Group type: OTHER
Intervention: AliveCor
Description: Device will be used in order to record an electrocardiogram during symptoms perceived to be AF. All patients will be instructed to transmit at least once per week.
Study: NCT05888038

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: virtual reality
Description: virtual reality
Study: NCT05467527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice
Description: The PACT group will receive a combination of 6 online modules and 4 group-based video conferencing sessions of Prosocial-orientated Acceptance and Commitment Training plus positive parenting advice via a mobile app across 12 weeks. The modules will cover real-life scenarios of daily parenting challenges in caring for a child with SHCN, followed by age-appropriate positive parenting advice based on the Centers for Disease Control and Prevention guidelines. After going through the scenarios, parents will be audio/visually guided to participate in ACT activities, including mindfulness exercises, ACT metaphors and experiential exercises, which will be used to increase psychological flexibility.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Positive parenting advice
Description: The Control Group will receive a total of 6 online modules and 4 group-based video conferencing sessions in a closed group of 6-8, 60 minutes per session guided by a trained facilitator via the mobile app across 12 weeks. The online modules will provide identical contents to those in the PACT group, but no guided ACT metaphors or experiential exercises. The interaction sessions serve to review and discuss the contents of online modules, but without the contents related to ACT/prosociality.
Study: NCT05452863

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: O2matic administered oxygen
Description: Oxygen supply is adjusted from an almost continuous measurement of the oxygen saturation with an appropriate an previously tested algorithm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Manual oxygen supply and adjustments
Description: Oxygen supply is adjusted from manual measurements of the oxygen saturation
Study: NCT03105713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient Safety Checklist
Description: The intervention is developed, validated and to be implemented in seven surgical clusters in two hospitals, in a stepped wedge cluster randomized controlled trial of the PASC for patients to use.
Study: NCT05784844

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: Carbapenem antibiotic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Micafungin
Description: Echinocandin antifungal
Study: NCT05296018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mandala coloring page
Description: Mandala program will be applied three days a week (30 minutes) for 8 weeks.
Study: NCT04890860

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
Description: cardiac surgery involving mitral or tricuspid valve repair procedure, with cardiopulmonary bypass
Study: NCT05781542

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sD-NP-GT8 DNA
Description: 0.4 mg or 1.6 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sD-NP-GT8 DNA
Description: 0.4 mg or 1.6 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: sD-NP-GT8 DNA
Description: 0.4 mg or 1.6 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA
Description: 0.1 mg or 0.4 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA
Description: 0.1 mg or 0.4 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12 DNA
Description: 0.1 mg or 0.4 mg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trimer 4571
Description: 100 mcg

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 3M-052-AF
Description: 5 mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alum
Description: 500 mcg
Study: NCT05535946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily, preferably in the morning, with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABX464
Description: Administered once daily, preferably in the morning, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily, preferably in the morning, with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ABX464
Description: Administered once daily, preferably in the morning, with food

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX464
Description: Administered once daily, preferably in the morning, with food

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered once daily, preferably in the morning, with food
Study: NCT05438849

Intervention type: BEHAVIORAL
Intervention: Mobile Health Application focused on behavioral treatments to treat urinary incontinence
Description: Mobile health application for cell phones and computers that delivers evidence-based behavioral treatment for urinary incontinence, specifically tailored to women Veterans

Intervention type: COMBINATION_PRODUCT
Intervention: Practice Facilitation
Description: The toolkit has 4 components: (1) Practice Facilitation Visits, (2) Mobile-health or mHealth Application Training (MAT) training, (3) Access and education on the Data Dashboard, and (4) Health information technology (HIT) assistance.
Study: NCT05155280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PET imaging using [11C]DASB radioligand.
Description: Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PET imaging using [11C]DASB radioligand.
Description: Subjects will be asked to complete a food choice task in PET/MRI. During the task, PET and MRI scans will be acquired simultaneously. This will allow us to see in real time during food choices the brain activations of the subjects. For imaging we will inject the DASB tracer intravenously. This radio ligand is a tracer that allows us to see the cerebral serotoninergic transmission by positron emission tomography.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Tracker
Description: The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Eye Tracker
Description: The second technique used is the eye tracker that will allow us to analyze food avoidance behaviors through the eyes. With a TOBII eye tracker we wil be able to follow the gaze of the subjects during the food preference task. It is a non-invasive approach.
Study: NCT05923125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded-Intensity Treadmill Exercise Protocol
Description: The exercise protocol will be administered by the principal investigator or other trained study staff under the supervision of the PI in the stress testing laboratory of NYU Langone Health - Tisch Hospital. The exercise protocol duration will vary by participant, but is likely to be between 8 and 25 minutes in duration.
Study: NCT05849142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRIdian Linac
Description: Radiation therapy (RT) will be delivered with an integrated MRI-RT delivery system (MRIdian Linac). Participants will then receive standard-of-care RT with a dose prescription of 70 Gy in 35 fractions on the MRIdian Linac. Adaptive RT (ART) planning will occur every 5th fraction of RT.
Study: NCT06185816

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Treatment
Description: The treatment is a non-invasive pulsed radio frequency current that emits a high frequency magnetic field. It has a pulse width of 0.2ms, a pulse rate of 2Hz and an intensity between 0 - 30ma. There is a 'beep' sound as the pulses occur. There are 2 electrodes used - one is the indifferent electrode that is placed on the skin at a suitable distance away from the active electrode and the other, an active electrode - is a probe that is applied to the target nerve to treat the mononeuropathy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Non-active Treatment
Description: The placebo device will be inert with nil current emitted however the device will look and be used in exactly the same way. There will also be a 'beep' sound emitted and only the investigator will know the difference. The placebo device will not deliver any electrical stimulation.
Study: NCT06001047

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group A
Description: Acupoint selection: The location of the vertigo-auditory area follows the positioning standard of Jiao Shunfa's Head Acupuncture. Operation: Electroacupuncture stimulation in the vertigo-auditory area of affected side. Pulse electrotherapy produced by Wujin Changcheng Medical Instrument. Sparse-dense waveforms are selected, with a voltage of 2-4V, a frequency of 60-80 times/min, and the intensity is determined by the patient's tolerance. The needle is in affected side for 30 minutes, and treatment is given once daily for a total of 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Group B
Description: The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol.
Study: NCT06600347

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DASH diet
Description: The participants will be treated with the DASH diet (1600-1800 calories/ day) for three months, in addition to antihypertensive drugs.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.
Study: NCT05688345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remimazolam
Description: The patient receives continuous infusion of remimazolam at a rate of 0.3-1.0 mg/kg/hr.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Patients are administered propofol at an effective site concentration of 1.0-2.5 mcg/ml through target-controlled infusion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: The patient is administered a dose of dexmedetomidine at 1 mcg/kg for 10 minutes, followed by continuous infusion at a rate of 0.2-1.0 mcg/kg/hr.
Study: NCT05951985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIFT
Description: Exercise sessions will be 60 to 75 minutes in duration and be a combination of resistance, aerobic, and balance exercise, with emphasis on functional movements performed at a high intensity. Exercises will be tailored/modified to meet the needs of each participant.
Study: NCT05209763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: More intensive rehabilitation
Description: Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: More intensive rehabilitation
Description: Patient exercises with physiotherapists, staff assists with normal activities during the day, activation, and mobilization in and out of bed according to the patient's ability.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: More intensive nutrition
Description: in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: More intensive nutrition
Description: in addition, the patient will be administered hydroxymethylbutyrate at a dose of 3 g/day - in case of ONS indication (oral nutrition support, formerly sipping) in this form (Ensure advance plus 2 times a day), in case of non-indication or impossibility or intolerance of this form then in the form of a food supplement (Myotec HMB). The minimum total dose delivered is 12 g/5 days.~* in case of hypovitaminosis D and serum Ca concentration up to 3.0 mmol/l, vitamin D will be administered at a dose of 3000 IU/day - cumulative 15000 IU/5 days (missing dose can be given at the end of the cycle in one dose)~* inclusion of probiotics in standard doses
Study: NCT06600347

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: The participants will be treated with progressive muscle relaxation for 30 minutes, 3 times/week for 3 months, in addition to antihypertensive drugs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti hypertensive drugs
Description: All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti hypertensive drugs
Description: All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti hypertensive drugs
Description: All participants in all groups will be treated with antihypertensive drugs as prescribed from the physician
Study: NCT06243458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVU120 (SEL120)
Description: RVU120 will be taken orally every other day (q.o.d). in a 21-day treatment cycle. Doses of RVU120 will be administered from day 1 to day 13 (total of 7 doses per cycle).
Study: NCT04577547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WL & exercise
Description: Intake of DGA weight loss 8 day rotating menu \& PAGA-recommended exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WL & no exercise
Description: Intake of DGA weight loss 8 day rotating menu \& no exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WM & exercise
Description: Intake of DGA weight maintenance 8 day rotating menu \& PAGA-recommended exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DGA diet WM & no exercise
Description: Intake of DGA weight maintenance 8 day rotating menu \& no exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WL & exercise
Description: Intake of Western-type weight loss 8 day rotating menu \& PAGA-recommended exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WL & no exercise
Description: Intake of Western-type weight loss 8 day rotating menu \& no exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WM & exercise
Description: Intake of Western-type weight maintenance 8 day rotating menu \& PAGA-recommended exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Western diet WM & no exercise
Description: Intake of Western-type weight maintenance 8 day rotating menu \& no exercise
Study: NCT04574050

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SELF-BREATHE
Description: A self -guided, internet -based intervention for patients with chronic breathlessness
Study: NCT04595968

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vestal DM Active device
Description: Battery powered non-invasive neurostimulation device

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Lifestyle modification
Description: Subjects are prescribed a low calorie (500kcal deficit) diet if their BMI is ≥25. If a subject has a BMI of ≤24.9, they will be provided with guidance on ensuring their recommended daily dietary intake is achieved throughout the course of the trial (i.e 2,500kcal/day for men and 2,000kcal/day for women)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Vestal DM Sham device
Description: Placebo comparator sham device (no active stimulation)
Study: NCT06190158

Intervention type: DIAGNOSTIC_TEST
Intervention: Oral sodium suppression test
Description: Oral sodium suppression test (\~2 grams of supplemental sodium for 3 days)

Intervention type: DIAGNOSTIC_TEST
Intervention: Saline suppression test
Description: Saline suppression test (2 liters of saline)

Intervention type: DIAGNOSTIC_TEST
Intervention: Captopril suppression test
Description: Captopril suppression test (50mg of captopril)

Intervention type: DIAGNOSTIC_TEST
Intervention: Dexamethasone suppression test
Description: 1mg of dexamethasone

Intervention type: DIAGNOSTIC_TEST
Intervention: Cosyntropin stimulation test
Description: 250mcg of cosyntropin
Study: NCT06281756

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: Subjects will receive therapy for 8 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Behavioral Treatment for Insomnia (CBT-I)
Description: Subjects will receive therapy for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: Non-remitting subjects will receive Trazodone (dosage) for 8 weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-remitting subjects will receive placebo for 8 weeks
Study: NCT06498583

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.25 % ropivacaine ( 0.5ml / kg )

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: 0.25 % ropivacaine ( 0.5ml / kg )

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: After the operation, unilateral erector spinae plane block was performed at the T5 level under ultrasound guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Incision infiltration of local anesthesia
Description: After the operation, Incision infiltration of local anesthesia is performed around the surgical incisions.
Study: NCT05002868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RP12146
Description: starting dose of 100 mg QD
Study: NCT05120830

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological NTLA-2002
Description: CRISPR/Cas9 gene editing system delivered by LNP for IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological NTLA-2002
Description: CRISPR/Cas9 gene editing system delivered by LNP for IV administration

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological NTLA-2002
Description: CRISPR/Cas9 gene editing system delivered by LNP for IV administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline IV Administration
Description: The administration of IV normal saline
Study: NCT06493578

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VYN201 Gel
Description: VYN201 Gel is a topical formulation applied as a thin layer to affected areas.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VYN201 Gel
Description: VYN201 Gel is a topical formulation applied as a thin layer to affected areas.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: VYN201 Gel
Description: VYN201 Gel is a topical formulation applied as a thin layer to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: VYN201 Gel
Description: VYN201 Gel is a topical formulation applied as a thin layer to affected areas.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Gel
Description: Vehicle gel (placebo) is matching in appearance to VYN201 gel and is to be applied in the same manner as VYN201 gel.
Study: NCT05316597

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Forest bathing
Description: Participants will be seated in a forest environment for an hour-long exposure to the forest

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Forest bathing
Description: Participants will be seated in a forest environment for an hour-long exposure to the forest